Dassault Systemes

Boehringer Ingelheim Selects Medidata Clinical Cloud® to Accelerate Innovation in Drug Development

Press Release
December 21, 2015
12/21/2015

Medidata’s Cutting-Edge Technology Platform Will Enable Top-20 Global Pharma to Conduct Faster, More Accurate and More Cost-Effective Clinical Trials

Selection of Medidata Underscores Boehringer Ingelheim’s Commitment to Deploy Best-in-Class Technology to Power Groundbreaking Medical Advances

NEW YORK, N.Y.– December 21, 2015 – Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Boehringer Ingelheim has selected the Medidata Clinical Cloud® to accelerate innovation across all of its drug development programs. The top-20 global pharmaceutical company will leverage Medidata’s technology platform to bring new insights and knowledge into multiple stages of the Boehringer Ingelheim drug development process, enabling its researchers to conduct faster, more accurate and more cost-effective clinical trials.

In supporting more than 10,000 clinical studies, 370,000 investigational sites and more than 2.7 million trial volunteers, the Medidata platform is driving a transformation in clinical trial design and execution, leading to better science and new medical breakthroughs for patients. Leveraging the power of this platform, Boehringer Ingelheim will integrate Medidata’s study planning, data management, data analytics and risk-based monitoring (RBM) capabilities into multiple stages of its drug development process.

“Boehringer Ingelheim creates therapeutic value through continuous innovation, so fortifying our R&D efforts with smart, agile technology is vital to our continued success,” said Klaus Stern, global head of Biostatistics & Data Sciences at Boehringer Ingelheim. “Medidata’s platform of cloud-based solutions and data analytics will increase the efficiency of our R&D and help us be more nimble in developing and conducting increasingly complex clinical trials. Ultimately, this can bring new medicines to patients sooner, which is what our team is working to do every day.”

Named one of Reuters' top 100 global innovators in 2015, Boehringer Ingelheim has deep therapeutic expertise in oncology, immunology and respiratory diseases, cardiometabolic diseases, and diseases of the central nervous system. To enhance its portfolio of Phase I-III and post-approval studies, Boehringer Ingelheim is adopting the Medidata Clinical Cloud platform, including its solutions for electronic data capture, management and reporting (Medidata Rave®); medical coding (Medidata Coder®); safety reporting (Safety Gateway); trial design (Medidata Designer®); and site budgeting and planning (Medidata Grants Manager®). The Company will also use one of Medidata’s turnkey clinical analytics offerings (Medidata Insights™), which provides advanced metrics, visualizations and the most powerful set of industry data and benchmarks. A phased rollout will begin in 2016.

Additionally, Boehringer Ingelheim will utilize solutions within Medidata RBM (including Medidata TSDV and Medidata SQM). These industry-leading tools for risk-based monitoring (RBM) will allow Boehringer Ingelheim to better prioritize resources around key areas of risk, such as patient safety and data quality and integrity. Boehringer Ingelheim has long been a proponent of RBM as a member of TransCelerate Biopharma, Inc. and as a representative within the non-profit’s risk-based monitoring work stream.

“Boehringer Ingelheim is committed to a faster and more flexible approach to R&D, and Medidata is excited to be a key partner in that effort for years to come,” said Medidata’s chief executive officer Tarek Sherif. “Our cloud technology and data-driven analytics deliver the features, the scale and the precise insights that Boehringer Ingelheim and a rapidly growing list of other global pharma companies need to develop exciting medical advances to improve people’s health and transform their lives.”

Connect with Medidata

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

For more information please visit www.boehringer-ingelheim.com

About Medidata
Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

Medidata Contacts:
Investor: Hulus Alpay, Medidata Solutions, +1 212-419-1025, halpay@mdsol.com
Media: Nicole Pariser, Medidata Solutions, +1 212-659-1069, npariser@mdsol.com